Table 3.

Radiological response and survival data during first-line treatment.

Response to TKI Therapy, n = 46
mOS [months]; (95% CI)	10.9 (6.9–14.9)
mPFS [months]; (95% CI)	5.7 (2.0–9.4)
Stable disease; n, (%)	8 (17.4)
Progressive disease; n, (%)	23 (50.0)
No staging performed; n, (%)	15 (32.6)
Disease control rate [%]	17.4
mTTP [months]; median, (range)	3.5 (1.1–38)